These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38502656)

  • 1. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
    Moodie Z; Andersen-Nissen E; Grunenberg N; Dintwe OB; Omar FL; Kee JJ; Bekker LG; Laher F; Naicker N; Jani I; Mgodi NM; Hunidzarira P; Sebe M; Miner MD; Polakowski L; Ramirez S; Nebergall M; Takuva S; Sikhosana L; Heptinstall J; Seaton KE; De Rosa S; Diazgranados CA; Koutsoukos M; Van Der Meeren O; Barnett SW; Kanesa-Thasan N; Kublin JG; Tomaras GD; McElrath MJ; Corey L; Mngadi K; Goepfert P;
    PLoS Med; 2024 Mar; 21(3):e1004360. PubMed ID: 38502656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.
    Chirenje ZM; Laher F; Dintwe O; Muyoyeta M; deCamp AC; He Z; Grunenberg N; Laher Omar F; Seaton KE; Polakowski L; Woodward Davis AS; Maganga L; Baden LR; Mayer K; Kalams S; Keefer M; Edupuganti S; Rodriguez B; Frank I; Scott H; Stranix-Chibanda L; Gurunathan S; Koutsoukos M; Van Der Meeren O; DiazGranados CA; Paez C; Andersen-Nissen E; Kublin J; Corey L; Ferrari G; Tomaras G; McElrath MJ
    J Infect Dis; 2024 Aug; 230(2):e405-e415. PubMed ID: 37795976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
    Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
    PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
    Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
    PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
    McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.
    Gray GE; Bekker LG; Laher F; Malahleha M; Allen M; Moodie Z; Grunenberg N; Huang Y; Grove D; Prigmore B; Kee JJ; Benkeser D; Hural J; Innes C; Lazarus E; Meintjes G; Naicker N; Kalonji D; Nchabeleng M; Sebe M; Singh N; Kotze P; Kassim S; Dubula T; Naicker V; Brumskine W; Ncayiya CN; Ward AM; Garrett N; Kistnasami G; Gaffoor Z; Selepe P; Makhoba PB; Mathebula MP; Mda P; Adonis T; Mapetla KS; Modibedi B; Philip T; Kobane G; Bentley C; Ramirez S; Takuva S; Jones M; Sikhosana M; Atujuna M; Andrasik M; Hejazi NS; Puren A; Wiesner L; Phogat S; Diaz Granados C; Koutsoukos M; Van Der Meeren O; Barnett SW; Kanesa-Thasan N; Kublin JG; McElrath MJ; Gilbert PB; Janes H; Corey L;
    N Engl J Med; 2021 Mar; 384(12):1089-1100. PubMed ID: 33761206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine Trial.
    Garrett N; Dintwe O; Monaco CL; Jones M; Seaton KE; Church EC; Grunenberg N; Hutter J; deCamp A; Huang Y; Lu H; Mann P; Robinson ST; Heptinstall J; Jensen RL; Pantaleo G; Ding S; Koutsoukos M; Hosseinipour MC; Van Der Meeren O; Gilbert PB; Ferrari G; Andersen-Nissen E; McElrath MJ; Tomaras GD; Gray GE; Corey L; Kublin JG;
    J Acquir Immune Defic Syndr; 2024 Aug; 96(4):350-360. PubMed ID: 38916429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
    Hosseinipour MC; Innes C; Naidoo S; Mann P; Hutter J; Ramjee G; Sebe M; Maganga L; Herce ME; deCamp AC; Marshall K; Dintwe O; Andersen-Nissen E; Tomaras GD; Mkhize N; Morris L; Jensen R; Miner MD; Pantaleo G; Ding S; Van Der Meeren O; Barnett SW; McElrath MJ; Corey L; Kublin JG;
    Clin Infect Dis; 2021 Jan; 72(1):50-60. PubMed ID: 31900486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.
    Zhao LP; Fiore-Gartland A; Carpp LN; Cohen KW; Rouphael N; Fleurs L; Dintwe O; Zhao M; Moodie Z; Fong Y; Garrett N; Huang Y; Innes C; Janes HE; Lazarus E; Michael NL; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; De Rosa SC; Corey L; Gray GE; Seaton KE; Yates NL; McElrath MJ; Frahm N; Tomaras GD; Gilbert PB
    PLoS One; 2020; 15(1):e0226803. PubMed ID: 31999736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
    Frank I; Li SS; Grunenberg N; Overton ET; Robinson ST; Zheng H; Seaton KE; Heptinstall JR; Allen MA; Mayer KH; Culver DA; Keefer MC; Edupuganti S; Pensiero MN; Mehra VL; De Rosa SC; Morris DE; Wang S; Seaman MS; Montefiori DC; Ferrari G; Tomaras GD; Kublin JG; Corey L; Lu S;
    Lancet HIV; 2024 May; 11(5):e285-e299. PubMed ID: 38692824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
    O'Connell RJ; Excler JL; Polonis VR; Ratto-Kim S; Cox J; Jagodzinski LL; Liu M; Wieczorek L; McNeil JG; El-Habib R; Michael NL; Gilliam BL; Paris R; VanCott TC; Tomaras GD; Birx DL; Robb ML; Kim JH
    J Infect Dis; 2016 Jun; 213(12):1946-54. PubMed ID: 26908741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
    Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
    PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney J; Seaman M; Montefiori DC; Labranche C; Yates NL; Shen X; Tomaras GD; Ferrari G; Foulds KE; McDermott A; Kao SF; Roederer M; Hawkins N; Self S; Yao J; Farrell P; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo A; Weiss D; Lee C; Kibler K; Jacobs B; Asbach B; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2015 Aug; 89(16):8525-39. PubMed ID: 26041302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
    Thongcharoen P; Suriyanon V; Paris RM; Khamboonruang C; de Souza MS; Ratto-Kim S; Karnasuta C; Polonis VR; Baglyos L; Habib RE; Gurunathan S; Barnett S; Brown AE; Birx DL; McNeil JG; Kim JH;
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):48-55. PubMed ID: 17909315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques.
    Phillips B; Van Rompay KKA; Rodriguez-Nieves J; Lorin C; Koutsoukos M; Tomai M; Fox CB; Eudailey J; Dennis M; Alam SM; Hudgens M; Fouda G; Pollara J; Moody A; Shen X; Ferrari G; Permar S; De Paris K
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
    AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.
    Pantaleo G; Janes H; Karuna S; Grant S; Ouedraogo GL; Allen M; Tomaras GD; Frahm N; Montefiori DC; Ferrari G; Ding S; Lee C; Robb ML; Esteban M; Wagner R; Bart PA; Rettby N; McElrath MJ; Gilbert PB; Kublin JG; Corey L;
    Lancet HIV; 2019 Nov; 6(11):e737-e749. PubMed ID: 31601541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
    Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
    Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.
    Fouda GG; Cunningham CK; McFarland EJ; Borkowsky W; Muresan P; Pollara J; Song LY; Liebl BE; Whitaker K; Shen X; Vandergrift NA; Overman RG; Yates NL; Moody MA; Fry C; Kim JH; Michael NL; Robb M; Pitisuttithum P; Kaewkungwal J; Nitayaphan S; Rerks-Ngarm S; Liao HX; Haynes BF; Montefiori DC; Ferrari G; Tomaras GD; Permar SR
    J Infect Dis; 2015 Feb; 211(4):508-17. PubMed ID: 25170104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.